Loading
MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.
Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Lung Adenocarcinoma, Pleural Mesothelioma, Prostate Adenocarcinoma.
In plain words · MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.
MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.
Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator.
No product in this corpus aims at MGA yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA MGA: RNA low tissue specificity; high antibody staining in 2 normal tissues. Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Mesothelioma, Prostate cancer, Lymphoma, Leukaemia, Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q8IWI9; CIViC gene MGA; IntOGen MGA; Human Protein Atlas MGA tissue; Open Targets ENSG00000174197 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1998, "Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro". Source.
Sources: HGNC HGNC:14010 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8IWI9 (protein name, function text, keywords and locations (REST API)); CIViC gene MGA (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen MGA (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Function activated by heterodimerisation with MAX. This heterodimerisation serves the dual function of both generating an E-box-binding heterodimer and simultaneously blocking interaction of a corepressor. Location: Nucleus (UniProt). Locus 15q15 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Bone marrow, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex, Cervix, Colon.
No cancer stained high; medium in breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MGA" OR ABSTRACT:"MGA" OR TITLE:"MAX dimerization protein MGA" OR ABSTRACT:"MAX dimerization protein MGA" OR TITLE:"MAX gene-associated protein" OR ABSTRACT:"MAX gene-associated protein" OR TITLE:"KIAA0518" OR ABSTRACT:"KIAA0518" OR TITLE:"MAD5" OR ABSTRACT:"MAD5" OR TITLE:"MXD5" OR ABSTRACT:"MXD5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MGA, not a curated reading list.
Shares Pleural mesothelioma, Mesothelioma, Prostate cancer, Non-small-cell lung cancer.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen, Diffuse large B-cell lymphoma.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.